Inventor · disambiguated record
Heinz-Josef Lenz
Also filed as: LENZ HEINZ-JOSEF
11 granted patents·39 pending applications·62 citations·filing 2001–2018
85Inventor score
Top patents by PatentIndex Score
50 records- 0186US7662553B2Polymorphisms in the ERCC1 gene for predicting treatment outcomeUNIV SOUTHERN CALIFORNIA·Filed 2003·Granted Feb 16, 2010·33 cites·12 claims
- 0285US6716581B2Manganese superoxide dismutase gene polymorphism for predicting cancer susceptibilityUNIV SOUTHERN CALIFORNIA·Filed 2001·Granted Apr 6, 2004·27 cites·15 claims
- 0379US7807364B2Angiogenesis pathway gene polymorphisms for therapy selectionUNIV SOUTHERN CALIFORNIA·Filed 2007·Granted Oct 5, 2010·1 cites·15 claims
- 0465US8568968B2EGFR polymorphisms predict gender-related treatmentLENZ HEINZ-JOSEF·Filed 2010·Granted Oct 29, 2013·1 cites·12 claims
- 0565US2008286789A1Genomic polymorphism for predicting therapeutic responseUNIV SOUTHERN CALIFORNIA·Filed 2008·Application pending·0 cites
- 0663US2010173922A1Polymorphisms for Predicting Disease and Treatment OutcomeUNIV SOUTHERN CALIFORNIA·Filed 2009·Application pending·0 cites
- 0762US8435752B2Gene polymorphisms predictive for dual TKI therapyLENZ HEINZ-JOSEF·Filed 2008·Granted May 7, 2013·0 cites·6 claims
- 0861US2013196955A1Polymorphisms for predicting disease and treatment outcomeLENZ HEINZ-JOSEF·Filed 2013·Application pending·0 cites
- 0960US2007218487A1Genetic markers for predicting disease and treatment outcomeUNIV SOUTHERN CALIFORNIA·Filed 2007·Application pending·0 cites
- 1058US2011105529A1ERCC-1 Gene Expression Predicts Chemotherapy OutcomeUNIV SOUTHERN CALIFORNIA·Filed 2009·Application pending·0 cites
- 1157US7727724B2Polymorphisms in voltage-gated sodium channel α 1-subunit as markers for therapy selectionUNIV SOUTHERN CALIFORNIA·Filed 2007·Granted Jun 1, 2010·0 cites·17 claims
- 1257US2004067519A1Manganese superoxide dismutase gene polymorphism for predicting cancer susceptibilityUNIV SOUTHERN CALIFORNIA·Filed 2003·Application pending·0 cites
- 1357US2011178110A1Genotype and Expression Analysis for Use in Predicting Outcome and Therapy SelectionUNIV SOUTHERN CALIFORNIA·Filed 2009·Application pending·0 cites
- 1455US2010104583A1Gene Polymorphisms in VEGF and VEGF Receptor 2 as Markers for Cancer TherapyUNIV SOUTHERN CALIFORNIA·Filed 2008·Application pending·0 cites
- 1555US2010152202A1Tissue Factor Promoter PolymorphismsUNIV SOUTHERN CALIFORNIA·Filed 2008·Application pending·0 cites
- 1654US8318426B2Polymorphisms in voltage-gated sodium channel alpha 1-subunit as markers for therapy selectionLENZ HEINZ-JOSEF·Filed 2010·Granted Nov 27, 2012·0 cites·7 claims
- 1754US2010184773A1Germline Polymorphisms in the Angiogenic Pathway Predict Tumor Recurrence in Cancer TherapyLENZ HEINZ-JOSEF·Filed 2008·Application pending·0 cites
- 1854US2011160216A1Thymidylate Synthase Haplotype is Associated with Tumor Recurrence in Stage II and Stage III Colon Cancer PatientsUNIV SOUTHEM CALIFORNIA·Filed 2008·Application pending·0 cites
- 1954US2010092485A1Genetic Markers for Predicting Responsiveness to Combination TherapyUNIV SOUTHERN CALIFORNIA·Filed 2008·Application pending·0 cites
- 2052US2010099720A1Gene Polymorphisms as Sex-Specific Predictors in Cancer TherapyLENZ HEINZ-JOSEF·Filed 2008·Application pending·0 cites
- 2151US2009181016A1FCgamma POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOMEUNIV SOUTHERN CALIFORNIA·Filed 2006·Application pending·0 cites
- 2251US2010233719A1Genetic Markers for Predicting Disease and Treatment OutcomeUNIV SOUTHERN CALIFORNIA·Filed 2010·Application pending·0 cites
- 2350US8357369B2Genetic markers for predicting responsiveness to combination therapyUNIV SOUTHERN CALIFORNIA·Filed 2011·Granted Jan 22, 2013·0 cites·14 claims
- 2449US2006115827A1Genetic markers for predicting disease and treatment outcomeUNIV SOUTHERN CALIFORNIA·Filed 2005·Application pending·0 cites
- 2549US2019233884A1Hent1 plus mate1/oct2 polymorphisms predict efficacy and toxicity of tas-102 in metastatic colorectal cancer patientsUNIV SOUTHERN CALIFORNIA·Filed 2018·Application pending·0 cites
- 2649US2012122946A1Polymorphisms for predicting disease and treatment outcomeLENZ HEINZ-JOSEF·Filed 2011·Application pending·0 cites
- 2748US10563267B2Polymorphism biomarkers predict clinical outcomes of cancer patients receiving regorafenibLENZ HEINZ JOSEF·Filed 2017·Granted Feb 18, 2020·0 cites·15 claims
- 2848US2014005064A1Polymorphisms in angiogenesis pathway genes associated with tumor recurrence in surgery treated cancer patientsLENZ HEINZ-JOSEF·Filed 2013·Application pending·0 cites
- 2947US2018311347A1Polymorphisms in cachexia predict clinical outcomes of colorectal cancer patients receiving irinotecan and bevacizumabUNIV SOUTHERN CALIFORNIA·Filed 2018·Application pending·0 cites
- 3047US2012094291A1FCgamma POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOMELENZ HEINZ-JOSEF·Filed 2011·Application pending·0 cites
- 3146US8278061B2Polymorphisms in the EGFR pathway as markers for cancer treatmentLENZ HEINZ-JOSEF·Filed 2008·Granted Oct 2, 2012·0 cites·5 claims
- 3246US8216781B2Gene polymorphisms as predictors of tumor progression and their use in cancer therapyLENZ HEINZ-JOSEF·Filed 2008·Granted Jul 10, 2012·0 cites·25 claims
- 3346US2012289410A1Genetic variant in formyl peptide receptor 2 (fpr2) predicts clinical outcome in cancer patientsLENZ HEINZ-JOSEF·Filed 2012·Application pending·0 cites
- 3446US2006051764A1Thymidylate synthase polymorphisms for use in screening for cancer susceptibilityMANDOLA MICHAEL·Filed 2003·Application pending·0 cites
- 3546US2013023430A1Cancer stem cell gene variants are associated with tumor recurrenceUNIV SOUTHERN CALIFORNIA·Filed 2012·Application pending·0 cites
- 3645US2012289424A1Igf1r polymorphism predicts tumor recurrence in breast cancer patientsLENZ HEINZ-JOSEF·Filed 2012·Application pending·0 cites
- 3744US2019161803A1Polymorphisms toll like receptor genes predicts clinical outcomes of colorectal cancer patientsUNIV SOUTHERN CALIFORNIA·Filed 2017·Application pending·0 cites
- 3844US2012129178A1Genomic polymorphism for predicting therapeutic responseLENZ HEINZ-JOSEF·Filed 2011·Application pending·0 cites
- 3943US2012107309A1Polymorphism in k-ras 3' untranslated region associated with clinical outcomes of cancer treatments independent of k-ras mutation statusLENZ HEINZ-JOSEF·Filed 2011·Application pending·0 cites
- 4042US2011020333A1Angiogenesis Pathway Gene Polymorphisms for Therapy SelectionUNIV SOUTHERN CALIFORNIA·Filed 2010·Application pending·0 cites
- 4141US2012289592A1Ercc1 gene expression level is associated with clinical outcomes in esophageal cancer patientsLENZ HEINZ-JOSEF·Filed 2012·Application pending·0 cites
- 4241US2012288861A1Germline polymorphisms in the sparc gene associated with clinical outcome in gastric cancerLENZ HEINZ-JOSEF·Filed 2010·Application pending·0 cites
- 4339US2012094844A1Genetic variants in il-6, p53, mmp-9 and cxcr predict clinical outcome in patients with cancerLENZ HEINZ-JOSEF·Filed 2010·Application pending·0 cites
- 4439US2012108441A1Polymorphisms in angiogenesis pathway genes associated with tumor recurrence in surgery treated cancer patientsLENZ HEINZ-JOSEF·Filed 2010·Application pending·0 cites
- 4539US2012077685A1Intratumoral gene expression levels of tp and vegf are associated with clinical outcomes in rectal cancer patients treated with 5-fluorouracil and pelvic radiationLENZ HEINZ-JOSEF·Filed 2011·Application pending·0 cites
- 4639US2012100997A1Cd133 polymorphisms and expression predict clinical outcome in patients with cancerLENZ HEINZ-JOSEF·Filed 2010·Application pending·0 cites
- 4739US2012108445A1Vegf and vegfr1 gene expression useful for cancer prognosisLENZ HEINZ-JOSEF·Filed 2010·Application pending·0 cites
- 4839US2012100134A1Genetic variants in angiogenesis pathway associated with clinical outcomeLENZ HEINZ-JOSEF·Filed 2010·Application pending·0 cites
- 4937US2012107308A1Gene expression levels of egfr, vegfr2, and ercc1 associated with clinical outcomes of chemotherapyLENZ HEINZ-JOSEF·Filed 2010·Application pending·0 cites
- 5036US2012100135A1Genetic polymorphisms associated with clinical outcomes of topoisomerase inhibitor therapy for cancerLENZ HEINZ-JOSEF·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →